Skip to content

Right ventricle to pulmonary artery conduit

FEASIBILITY AND OUTCOME OF TRICUSPID VALVED POLYTETRAFLUOROETHYLENE RIGHT VENTRICLE TO PULMONARY ARTERY CONDUCT

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/07/014941
Enrollment
30
Registered
2018-07-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Q255- Atresia of pulmonary artery Health Condition 2: Q200- Common arterial trunk Health Condition 3: null- Cyanotic Congenital Heart Disease with Pulmonary atresia or RVOT hypoplasia requiring RV to PA conduit Health Condition 4: Q220- Pulmonary valve atresia

Interventions

Intervention1: Right Ventricle to Pulmonary Artery conduit: Tricuspid polytetrafluoroethylene membrane valved autologous pericardial Right Ventricle to Pulmonary Artery conduit Control Intervention1:

Sponsors

Prof Shyam Kumar Singh Thingnam
Lead Sponsor
Dr Vikas Kumar
Collaborator
Prof Rohit Kumar Manoj
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All patients diagnosed with congenital heart disease with loss of continuity between right ventricle and pulmonary arteries, severe pulmonary stenosis or atresia or RVOT hypoplasia requiring RVOT reconstruction with right ventricular to pulmonary artery conduit.

Exclusion criteria

Exclusion criteria: 1. Absent central pulmonary arteries 2. Age > 18 years 3. Patients who will not give informed consent 4. Redo or primary cases in which autologous pericardium will not be sufficient for conduit construction

Design outcomes

Primary

MeasureTime frame
all cause mortality at 1 and 3 yearsTimepoint: all cause mortality at 1 and 3 years

Secondary

MeasureTime frame
a. Conduit function as assessed by Transthoracic echocardiography measuring post-operative peak and mean pressure gradients across the valve and valvular insufficiency b. Freedom from re-intervention either percutaneous or surgicalTimepoint: every 6 months

Countries

India

Contacts

Public ContactVikas Kumar

Post Graduate Institute of Medical Education and Research, Chandigarh

vikasctvs@yahoo.com8194934888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026